Abstract
Preeclampsia (PE) is a leading cause of maternal and fetal mortality and morbidity. While placental dysfunction is a core underlying issue, the pathogenesis of this disorder is thought to differ between early-onset (EOPE) and late-onset (LOPE) subtypes. As recent reports suggest that small extracellular vesicles (sEVs) contribute to the development of PE, we have compared systemic sEV concentrations between normotensive, EOPE, and LOPE pregnancies. To circumvent lengthy isolation techniques and intermediate filtration steps, a streamlined approach was developed to evaluate circulating plasma sEVs from maternal plasma. Polymer-based precipitation and purification were used to isolate total systemic circulating maternal sEVs, free from bias toward specific surface marker expression or extensive subpurification. Immediate Nanoparticle Tracking Analysis (NTA) of freshly isolated sEV samples afforded a comprehensive analysis that can be completed within hours, avoiding confounding freeze–thaw effects of particle aggregation and degradation.
Rather than exosomal subpopulations, our findings indicate a significant elevation in the total number of circulating maternal sEVs in patients with EOPE. This streamlined approach also preserves sEV-bound protein and microRNA (miRNA) that can be used for potential biomarker analysis. This study is one of the first to demonstrate that maternal plasma sEVs harbor full-length hypoxia inducible factor 1 alpha (HIF-1α) protein, with EOPE sEVs carrying higher levels of HIF-1α compared to control sEVs. The detection of HIF-1α and its direct signaling partner microRNA-210 (miR-210) within systemic maternal sEVs lays the groundwork for identifying how sEV signaling contributes to the development of preeclampsia. When taken together, our quantitative and qualitative results provide compelling evidence to support the translational potential of streamlined sEV analysis for future use in the clinical management of patients with EOPE.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
PE is a life threatening, pregnancy-specific condition that occurs in 4–7% of women worldwide [1,2,3,4,5]. Pathologic indications of PE are rapid, new onset hypertension after 20 weeks of gestation with accompanying proteinuria or maternal renal, pulmonary, or neurological involvement in the absence of proteinuria [6, 7]. This condition is one of the leading causes of maternal and fetal morbidity and mortality, and both preeclamptic mothers and their offspring are at higher risk of developing cardiovascular or metabolic diseases later in life [8,9,10,11,12]. The only cure for PE is delivery of the placenta [6, 7, 13]. No current treatment strategies or predictive measurements have proven to be successful in the clinical management of PE, emphasizing the substantial need to determine how this condition originates and how it can be identified.
At least two subtypes of PE are generally accepted to distinguish between patients diagnosed before 34 weeks of gestation (early-onset/EOPE) and patients diagnosed after 34 weeks of gestation (late-onset/LOPE) [6, 14,15,16,17]. A study by Benton et al., reported heterogenous placental profiles of PE using gene array [18]. However, a more recent report by He et al. using single cell sequencing analysis has indicated that when compared to LOPE, patients diagnosed with EOPE represent a more homogenous disease subtype primarily characterized by prolonged dysregulation of hypoxia-related signaling in the placenta after the first trimester [19]. Placental dysfunction as a result of reduced placental perfusion, oxidative stress, and/or hypoxia constitutes “compromised placental oxygen signaling” and likely acts as a primary driver of the pathogenesis of EOPE [19,20,21,22,23].
HIF-1α, a transcription factor essential for embryonic and placental development as well as fetal survival, is a critical molecular mediator of oxygen sensing. HIF-1α protein is significantly elevated in placental tissues after the first trimester in EOPE pregnancies [19, 22, 24,25,26,27,28,29,30,31]. EOPE placentas are reported to exhibit significantly higher levels of microRNA-210-3p (miR-210), a hypoxia-responsive microRNA which has been shown to form a positive signaling feedback loop with HIF-1α [32, 33]. Although inappropriate overactivation of hypoxia-related signaling in the placenta is a common feature of EOPE, it is not yet clear how placental HIF-1α may lead to maternal pathogenesis.
Maternal-placental communication normally occurs throughout gestation and is mediated in part by extracellular vesicles (EVs). EVs are lipid-bilayer nanoparticles that are secreted into circulation via numerous cell types and have been shown to be involved in intercellular communication by carrying biological cargo such as proteins, mRNA, and miRNA [34,35,36,37,38,39,40,41,42,43,44]. Although a multitude of distinct EV subpopulations have been identified, current research indicates that small extracellular vesicles (sEVs) play a central role in normal and pathological cell-to-cell communication [44,45,46,47,48]. sEVs are less than 200nm in size and include endocytic exosome (50-150nm) and plasma membrane microvesicle (100-200nm) subtypes [39, 43, 48,49,50]. Plasma sEV concentration has been shown to increase physiologically as a healthy pregnancy progresses, partly due to the growing placenta continually shedding vesicles into the maternal circulation [23, 40, 51, 52]. However, dysregulated sEV signaling has been reported to contribute to the pathogenesis of pregnancy-related disorders including gestational diabetes and PE [41, 48, 53,54,55,56,57].
Numerous methods of extracellular vesicle isolation and analysis have been utilized to further investigate the associations between sEV dysregulation and PE; however, sEVs are diverse in nature and no bona fide surface markers have been identified to differentiate between exosomal sEV and microvesicular sEV subpopulations [50, 58]. Many of the reported techniques for sEV analysis isolate specific subpopulations or require expensive instrumentation, large plasma volume input, and lengthy isolation steps that make it challenging to evaluate sEV data in a clinically useful manner [34,35,36]. Pregnant patient sEV analysis can vary significantly depending on the specific method of isolation and the intended readout and use of that information.
To circumvent sEV isolation techniques which have restrictive time, labor, or technological limitations, we have identified a streamlined approach to evaluate the total circulating concentration of maternal plasma sEVs in pregnancies complicated by early and late onset preeclampsia. This streamlined approach bypasses lengthy ultracentrifugation and size-exclusion procedures by employing polymer-based precipitation and subsequent bipartite resin column purification to rapidly produce high-yield sEV samples. Our technique eliminates excess filtration and surface-marker based sorting steps, giving a novel comprehensive representation of total systemic maternal sEVs that is unbiased towards sEV subpopulations. In addition, cargo held by sEVs isolated using this streamlined approach can be analyzed to assess the functional activity and predictive power of specific biomarkers relevant to the pathogenesis of PE. Using freshly isolated sEVs further avoids particle aggregation and degradation caused by storage conditions or repeated freeze-thawing [59]. Importantly, we believe this approach can be used to benefit PE patient management when applied in relevant clinical situations.
Methods
Study Groups and Samples
The population under study consisted of mothers aged 18–40 with singleton pregnancies: 14 healthy pregnant patients (Control) and 12 PE patients, with all donating samples between 24 and 39 weeks of gestation. 8 PE patients were identified as early-onset preeclamptic (EOPE) due to symptom onset prior to 34 weeks of gestation. 4 PE patients were identified as late-onset preeclamptic (LOPE) due to symptom onset after 34 weeks of gestation. While the gestational age at sample collection was not statistically different between study groups, the gestational age at delivery did differ (p < 0.001) (Table 1).
All subjects were informed and gave written consent prior to their participation in this study at Miami Valley Hospital, a high-risk maternity referral center in Dayton, Ohio USA. This study was reviewed and approved by the Wright State University Institutional Review Board. Patients with autoimmune diseases, chronic hypertension, recurrent miscarriages, preterm premature rupture of membranes (PPROM), or Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) syndrome were excluded from this study.
PE was diagnosed based on the International Society for the Study of Hypertension in Pregnancy (ISSHP) criteria and identified as new-onset hypertension with two repeated systolic blood pressure measurements ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg with coinciding proteinuria occurring after 20 weeks of gestation in previously normotensive patients or with indications of maternal renal, hepatic, or neurological involvement in the absence of proteinuria [60] (Table 1).
Plasma Collection
Blood was drawn in K2/EDTA tubes, mixed well by inversion, placed on ice and centrifuged within 5 min at 1,500g for 10 min at room temperature to obtain platelet-rich plasma. After a subsequent centrifugation at 3,000g for 10 min, platelet-free plasma was aliquoted and stored at -80°C until sEV isolation and analysis. Plasma with visible hemolysis was excluded from analysis.
sEV Isolation
Isolation, purification, and analysis of sEVs was performed in accordance with the guidelines recommended by the International Society for Extracellular Vesicles (ISEV) [39]. sEVs were isolated from platelet-free maternal plasma using ExoQuick Ultra (Systems Biosciences, #EQULTRA-20A-1) according to the manufacturer’s directions. Briefly, after centrifugation for 30 min at 14,500g to remove cellular debris, maternal plasma was combined with precipitation solution and incubated for 30 min at 4°C. Following incubation, samples were centrifuged for 10 min at 3,000g to obtain EV pellets. EV pellets were resuspended and loaded onto purification columns. A final centrifugation at 1,000g for 30 s yielded purified sEV samples (Fig. 1). Purified sEVs were immediately diluted for Nanosight analysis or stored at -80°C for downstream applications.
Nanoparticle Tracking Analysis (NTA)
Extracellular vesicle size and concentration were evaluated using a Nanosight NS300 (Malvern Panalytical Instruments, UK) equipped with a 488 nm laser. NTA 3.4 software version was used to record and analyze sample videos. NTA tracking analysis measures the rate of Brownian motion of nanoparticles using light scattering to provide a reproducible and specific analysis of nanoparticle size and concentration [61]. Phosphate buffered saline (1X PBS) was twice filtered using 0.02 μm Anotop 25 syringe filters (Whatman, #6809–2102) and used to dilute plasma-derived sEVs. Measurements were performed with filtered PBS to confirm the absence of background particles. Samples were diluted in order to achieve 20–100 particles/frame. Final data were averaged from three recorded 30-s capture videos taken for each patient’s sEV sample. All capture videos were analyzed with detection threshold 3 and camera level 10. A minimum of 300 tracks per video were taken and samples were analyzed in triplicate.
Western Blotting
Purified sEV samples were incubated on ice in 10X RIPA buffer supplemented with protease inhibitor cocktail (Cell Signaling Technology, #9806) and proteosome inhibitor MG-132 (Sigma, #M7449). Either 4X reducing sample buffer or 4X LDS non-reducing sample buffer (Thermo Scientific, #84,788) was added to the sEVs before heating at 95°C for five minutes. sEV samples were electrophoresed on SDS–polyacrylamide gels and subsequently transferred to a methanol-activated Immobilon-P Transfer Membrane (#IPVH00010 Immobilon). After blocking at room temperature for one hour with blocking buffer (1X TBS pH 7.6 containing 0.05% Tween-20 and 5% fat-free dry milk), membranes were incubated at 4°C with rocking overnight using primary antibodies for the following proteins: ALIX (1/1,000, Proteintech #67,715–1-Ig), β-Actin (1/10,000, Santa Cruz Biotechnology, #sc-47778), CD-9 (1/1,000, Proteintech #20,597–1-AP), Flotillin 1 (1/1,000, Proteintech #15,571–1-AP), GAPDH (1/2,000, Cell Signaling Technology #5174), Hif-1α (1/1,000, Novus Biologicals #NB100-449), placental alkaline phosphatase (1/1,000, Boster Biological Technology #A01718), TSG101 (1/1,000, Proteintech #28,283–1-AP). Following incubation, membranes were subsequently washed and incubated with secondary antibody at 1/10,000 for 1 h at room temperature and visualized via West Pico SuperSignal chemiluminescence.
sEV miRNA Isolation and Analysis
Extracellular vesicle miRNA was isolated by Trizol-chloroform separation and silica spin-column extraction using 200ul of isolated plasma sEVs and miRNeasy Serum/Plasma Kit (Qiagen, #217,184) following the manufacturer’s instructions. RNA was eluted from the silica spin-column in nuclease free water. RNA concentration and purity was assessed by UV–Vis using NanoDrop One (Thermo Scientific). MiRNA-210-3P cDNA was synthesized using 3ul of isolated EV RNA, 3ul of the stem-loop RT primer from the Hsa-miRNA-210-3P qPCR Assay (ThermoFisher, #000512, PN: 4,427,975), and Taqman MicroRNA RT kit (ThermoFisher, #4,366,596). The resulting mixture was placed in a thermal cycler and incubated at 16°C for 30 min, 42°C for 30 min, and 85°C for 5 min. The resulting miRNA-210-3P cDNA was stored at 4°C until PCR amplification. MicroRNA cDNA synthesis was performed in conjunction with a no-template and a no-RT control. PCR amplification of isolated EV miRNA-210-3P was performed using cDNA, qPCR assay primers from the Taqman Hsa-miRNA-210-3P assay, and PCR Master Mix Fast Advanced (ThermoFisher, #4,444,556). The reaction mixtures were thermal cycled 35 times with a 5 s denature step at 95 °C and an annealing and extension period for 30 s at 60 °C. The resulting product was electrophoresed on a 4% w/v agarose gel containing ethidium bromide for 90 min. The presence of the approximately 50 bp product signified the presence of miRNA-210-3P in human plasma-derived sEVs. The absence of a band in the no-template and no-RT controls signified the amplification was due to the presence of the miRNA in isolated EVs and not the result of off-target amplification.
Statistics
All data are reported as mean ± standard error of mean (SEM). GraphPad Prism 10 software was used for statistical analysis. Significance was determined between two group means by unpaired t-test, or between multiple group means by 1-way analysis of variance (ANOVA) with post hoc Bonferroni correction test to evaluate for pairwise comparisons. A p-value < 0.05 was considered statistically significant.
Results
Quantitative sEV Characterization
A streamlined approach was taken to rapidly isolate and analyze purified sEVs from Control, EOPE, and LOPE patient plasma. NTA indicated no significant differences in the average size of plasma sEVs from Control (108.6nm ± 3.6nm), EOPE (115.5nm ± 8.3nm), and LOPE (107.6nm ± 3.4nm) patients (Fig. 2A). The mode sizes of Control (82.5 ± 3.7nm), EOPE (91.9nm ± 6.1nm), and LOPE (90.0nm ± 1.6nm) sEVs also showed no significant variation (Fig. 2B). In addition to the mean and mode size measurements, representative particle size distribution graphs produced by NTA for individual patients from each study population indicates that our streamlined method reliably isolates sEVs less than 200nm and that these results are similar between PE and normotensive pregnancies (Fig. 2C).
Qualitative sEV Characterization
In addition to NTA size analysis, Western blotting was used to confirm sEV isolation from maternal plasma. Purified sEVs from Control, EOPE, and LOPE patients contained protein markers indicative of exosome biogenesis including the membrane-associated scaffolding protein flotillin-1, the tetraspanin protein CD9, and the endosomal accessory protein ALIX (Fig. 3). TSG101, a major component of the endosomal sorting complex required for transport (ESCRT) that commonly signifies exosomal and microvesicular sEV subpopulations, was present within control, EOPE and LOPE sEV samples (Fig. 3). Control, EOPE, and LOPE sEVs were negative for cytosolic housekeeping proteins B-actin and glyceraldehyde-3-phosphate dehydrogenase (Fig. 3). Placental alkaline phosphatase protein (PLAP), a marker of placental-derived extracellular vesicles, was detected within Control, EOPE, and LOPE plasma sEVs (Fig. 3) [53]. The presence of these markers provides confirmation that sEVs isolated from maternal plasma include exosomal subpopulations, as well as sEVs originating from placental tissue. Although Western blots were not quantified due to lack of a universal marker, sEV samples from EOPE and LOPE patients were highly enriched in PLAP and TSG101 when compared to Control plasma sEVs (Fig. 3).
Maternal Plasma sEV Concentration Analysis
NTA analysis revealed that sEVs from EOPE patients were significantly elevated when compared to normotensive pregnancies. Our data indicate that the concentration of sEVs in EOPE pregnancies (7.5 × 1011 ± 1.8 × 1011 particles/ml) is 5 times the amount present in Control pregnancies (1.5 × 1011 ± 3.7 × 1010 particles/ml, p = 0.0010, Fig. 4). There was no statistically significant difference between LOPE and normotensive pregnancies (Fig. 4). In addition, no significant differences were present when LOPE was compared to EOPE (p = 0.6187, Fig. 4).
Detection of HIF-1α and miR-210 in sEVs
Upregulation of both HIF-1α and miR-210 has been implicated in oxidatively-compromised placentas and is thought to underly EOPE pathogenesis [2, 22, 24,25,26,27,28, 30, 31, 33, 62,63,64,65,66]. It is largely unknown whether excessive HIF-1α protein in preeclamptic placentas could bypass degradation and travel systemically to transcriptionally modify other tissues in normoxia. As our results indicated that patients with EOPE have significantly more plasma sEVs in circulation than normotensive pregnancies, we wanted to determine whether plasma sEVs could serve as a potential transport system for HIF-1α protein or its target substrates. sEV lysis and subsequent Western blotting revealed that stabilized full length HIF-1α protein is present within EOPE and Control sEVs (Fig. 5A). EOPE patient sEVs had significantly higher levels of HIF-1α protein than Control patient sEVs (p = 0.0170, Fig. 5A).
HIF-1α signaling is known to induce production of miR-210, and placental miR-210 upregulation has also been extensively linked with EOPE pathogenicity [32, 33, 66,67,68,69,70,71,72,73,74,75,76]. To further explore the potential for sEVs to participate in HIF-1α-mediated signaling, we extracted sEV-bound small RNAs to then determine if hypoxia-inducible miR-210 was also located within maternal plasma sEVs. Our data indicate that miR-210 was detected in plasma sEVs from Control and EOPE pregnancies (Fig. 5B).
Discussion
EVs are lipid bilayer-enclosed structures produced from endocytic formation or from direct cellular plasma membrane blebbing. Upon their release into circulation, EVs are capable of carrying a wide variety of cargo capable of participating in cellular signaling [37, 42,43,44,45,46,47, 58, 77, 78]. There is now widespread recognition that EVs less than 200 nm in size, defined as sEVs, significantly contribute to cell-to-cell communication through the delivery of bioactive contents to downstream target tissues [42, 43, 78,79,80].
In the setting of human pregnancy, plasma EV concentrations are known to increase physiologically [48, 52, 81,82,83,84]. As a healthy pregnancy progresses, the placenta releases EVs into circulation as a means of communicating with maternal organs and promoting the various physiologic adaptations necessary to support the growing fetus [48, 51, 52, 85]. In vitro studies support advantageous sEV signaling in pregnancy: placental sEVs may be beneficially immunomodulatory and may function to enhance maternal spiral artery remodeling [77, 81, 84]. Conversely, there is now also wide-spread evidence demonstrating the pathologic impact of sEV signaling in the pathogenesis of pregnancy-related disorders including gestational diabetes and PE [23, 41, 42, 54, 55, 78,79,80, 86,87,88,89,90,91,92].
PE is pregnancy-specific de novo hypertension with concomitant signs of maternal organ involvement occurring after 20 weeks of gestation; the early onset subtype of PE occurring before 34 weeks of gestation is thought to have different underlying issues than those associated with the late onset subtype of PE diagnosed after 34 weeks of gestation [6, 14, 17, 19, 22, 60]. LOPE occurs in approximately 70% of PE patients and generally is associated with normal placental development [15, 20, 93]. EOPE makes up the most severe cases occurring in 15–20% of PE patients and is strongly associated with abnormal placental development and compromised placental oxygen signaling [2, 6, 14, 15, 60, 94].
Regardless of onset subtype, preeclamptic placentas are believed to communicate host organ damage to distant maternal tissues through modified sEV production and release [51, 87, 88, 90, 95]. The dynamic release of sEVs in reaction to maternal organ dysfunction, along with the stability of sEVs and their cargo within biological fluids such as plasma, has brought attention to utilizing noninvasive liquid biopsies and sEV characterization for diagnosing or monitoring the progression of pregnancy-related disorders including PE [37, 53, 80, 88, 90]. Specific sEV subpopulations, such as PLAP + syncytiotrophoblast-derived microparticles (STBMs) and CD68 + exosomes, have been reported to be elevated in PE patient plasma [23, 53, 86, 96,97,98,99,100]. However, isolating and quantifying sEV subpopulations is often labor-and time-intensive making it difficult to implement in a clinical setting.
As a reproducible approach to sEV analysis, we opted to streamline the isolation and quantification of plasma sEVs from normotensive and preeclamptic pregnancies. With minimal volume input and greatly reduced sample handling time, we have identified that EOPE pregnancies are associated with a significant increase in maternal plasma sEVs. The concentration values reported in this study represent measurements of circulating sEVs smaller than 200nm as detected by NTA, accounting for overlapping sEV subpopulations. While our approach to sEV isolation was conducted independent of surface protein expression, our results from Western blot confirm that various markers associated with exosomal, microvesicular, and placental-derived EV subtypes were present in our samples after purification. Aside from previously reported increases in particular sEV subpopulations, the significant increase in total plasma sEV concentrations we have identified in EOPE patients could suggest that the early onset PE phenotype may also be associated with systemically augmented maternal end organ sEV production.
The variable significance between EOPE and LOPE sEV concentrations versus Control sEV concentrations that we report are consistent with distinct pathogeneses of each PE subtype. LOPE patients generally have normal placentation, but excessive fetal metabolic demand late in the third trimester is thought to overwhelm the functional capacity of the placenta and cause placental cell stress without evidence of abnormal maternal perfusion [15, 23, 93]. In contrast, abnormal placentation and reduced perfusion due to compromised placental oxygen signaling are thought to contribute to the pathogenesis that primarily characterizes early onset PE phenotypes [19, 22, 30, 55, 93, 96]. Shallow decidual invasion and incomplete spiral artery remodeling are key pathogenic features underlying EOPE, and EOPE placentas commonly exhibit signs of oxidative placental cell stress [10, 15, 22, 25, 27, 28, 30, 62].
Numerous studies have consistently reported that HIF-1α protein, a master regulator of oxygen sensing, is significantly elevated in placental tissues after the first trimester in EOPE patients when compared to normotensive controls [22, 24,25,26,27,28,29,30, 63]. Although HIF-1α signaling is essential in the early stages of pregnancy, increased oxygenation at around 10 weeks of gestation normally leads to rapid HIF-1α protein degradation in the placenta; however, persistent stabilization and elevation of placental HIF-1α protein beyond the low-oxygen intrauterine environment of the first trimester is strongly associated with the pathogenesis of EOPE [2, 22, 24,25,26,27,28,29,30,31, 63, 64, 66]. Recent animal models have further reinforced this notion: trophoblast-specific HIF-1α overexpression, as well as conditional knockout of prolyl hydroxylase domain protein 2, result in pathologic HIF-1α stabilization and consequently induce EOPE-like symptoms in mice [2, 31].
In addition to elevated HIF-1α protein stabilization, EOPE is associated with abnormal expression of hypoxia-responsive miRNAs in the placenta [19, 24, 27, 33, 63]. Typically comprised of 22–25 nucleotides, miRNAs are small non-coding RNA molecules capable of translationally modifying gene expression through direct binding at the 3’-untranslated region (UTR) of mRNA [33, 69, 75, 101]. Although many placental miRNAs have been shown to be dysregulated in PE, abnormal upregulation of the hypoxia-responsive miR-210 in placental tissues has been particularly associated with EOPE [32, 33, 67, 69]. Hypoxic activation of miR-210 has been reported to occur via a HIF-1α-dependent mechanism [66]. miR-210 overexpression further induced HIF-1α protein stabilization, creating a positive feedback loop that exacerbated downstream activation of numerous hypoxia-related signaling pathways [33]. While pathologic upregulation of both miR-210 and a HIF-1α has been extensively implicated in the placental dysfunction that occurs in EOPE, it is not yet clear how the placenta communicates with other organ systems to relay compromised placental oxygen signaling and induce maternal pathophysiology [10, 19, 27, 32, 33, 71, 86, 102].
However, studies conducted by Aga et al. revealed that human nasopharyngeal carcinoma and epithelial cell lines were able to package full-length HIF-1α in sEVS [103]. Furthermore, studies by Ferreira et al. demonstrated that full-length HIF-1α protein released from sEVs retained functionality independent of oxygen tension [103, 104]. These reports indicate that HIF-1α protein is protected from degradation when packaged within sEVs and that sEV-bound HIF-1α is functionally capable of modifying its downstream signaling when taken up by target cells in normoxia [103, 104]. Biró et al. further detected the presence of miRNA-210 in an exosomal CD63 + subpopulation [71]. When considering the placenta’s continuous release of EVs throughout pregnancy, the characteristic elevation of placental HIF-1α protein and miR-210 seen in EOPE placentas may lead to preferential packaging of these molecules into sEVs for secretion into maternal circulation. Upon maternal tissue uptake, intracellular release of sEV-bound HIF-1α and miRNA-210 could initiate inappropriate hypoxia-related signaling and further dysregulate systemic sEV secretion. While further investigation is required to validate the pathogenicity of sEV-bound HIF-1α and miR-210, our studies represent a promising first step in elucidating the molecular origins of EOPE.
Our studies are the first to report that full-length HIF-1α protein is present in maternal plasma sEVs during pregnancy. Moreover, we found that HIF-1α protein was significantly elevated in sEVs from patients with EOPE compared to normotensive pregnancies. In addition to HIF-1α, we have shown its downstream target, miR-210, is also encapsulated and present systemically in maternal sEVs. These results suggest that sEVs structurally protect HIF-1α and miR-210 from systemic degradation.
In conclusion, we have utilized a rapid and reliable streamlined approach to analyze maternal plasma from pregnant patients and have determined that sEVs are significantly elevated in the maternal plasma of EOPE patients and contain HIF-1α and its direct target miR-210. The rapidity and reliability of sEV quantification and characterization offered by this approach is a significant advance when working with pregnancy-related disorders such as PE, as it can provide a greater potential for detection leading to earlier medical interventions to prolong pregnancy and minimize preterm birth-related complications.
Our study has some limitations in that plasma was collected from a small sample size and analyzed at a single gestational time point. Although these limitations exist, findings from this study provide compelling evidence that our streamlined approach to comprehensively assess maternal sEVs from minimally invasive liquid biopsies can distinguish a significant sEV elevation in EOPE pregnancies when compared to normotensive pregnancies. These results open the door for future studies with expanded sample sizes and longitudinal sEV analysis to aid in the clinical management of EOPE. This report provides novel insight into the potential genesis of EOPE: as the presence of full-length HIF-1α protein in conjunction with miR210 in circulating maternal sEVs may explain how compromised placental oxygen signaling may lead to pathophysiologic responses in downstream maternal tissues.
Data Availability
All data and material are available upon request.
Code Availability
Not applicable.
References
Waker CA, Kaufman MR, Brown TL. Current state of preeclampsia mouse models: approaches, relevance, and standardization. Front Physiol. 2021;12. https://doi.org/10.3389/fphys.2021.681632.
Albers RE, Kaufman MR, Natale BV, Keoni C, Kulkarni-Datar K, Min S, et al. Trophoblast-specific expression of hif-1α results in preeclampsia-like symptoms and fetal growth restriction. Sci Rep. 2019;9. https://doi.org/10.1038/s41598-019-39426-5.
Waker CA, Hwang AE, Bowman-Gibson S, Chandiramani CH, Linkous B, Stone ML, et al. Mouse models of preeclampsia with preexisting comorbidities. Front Physiol. 2023;14. https://doi.org/10.3389/fphys.2023.1137058.
Levine RJ, Lam C, Qian C, Maynard SE, Sachs BP, Epstein FH, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005.
McCarthy FP, O’Driscoll JM, Seed PT, Placzek A, Gill C, Sparkes J, et al. Multicenter cohort study, with a nested randomized comparison, to examine the cardiovascular impact of preterm preeclampsia. Hypertension. 2021;78:1382–94. https://doi.org/10.1161/HYPERTENSIONAHA.121.17171.
Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4:97–104. https://doi.org/10.1016/j.preghy.2014.02.001.
Espinoza J, Vidaeff A, Pettker C, Simhan H. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 2020;135:E237–60. https://doi.org/10.1097/AOG.0000000000003891.
Hakim J, Senterman MK, Hakim AM. Preeclampsia is a biomarker for vascular disease in both mother and child: the need for a medical alert system. Int J Pediatr. 2013;2013:1–8. https://doi.org/10.1155/2013/953150.
Backes CH, Markham K, Moorehead P, Cordero L, Nankervis CA, Giannone PJ. Maternal preeclampsia and neonatal outcomes. J Pregnancy. 2011;2011:214365. https://doi.org/10.1155/2011/214365.
Tomimatsu T, Mimura K, Endo M, Kumasawa K, Kimura T. Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. Hypertens Res. 2017;40:305–10. https://doi.org/10.1038/hr.2016.152.
Tabacco S, Ambrosii S, Polsinelli V, Fantasia I, D’Alfonso A, Ludovisi M, et al. Pre-eclampsia: from etiology and molecular mechanisms to clinical tools—a review of the literature. Curr Issues Mol Biol. 2023;45:6202–15. https://doi.org/10.3390/cimb45080391.
Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, De Groot CJM, Hofmeyr GJ. Pre-eclampsia. The Lancet. 2016;387:999–1011. https://doi.org/10.1016/S0140-6736(15)00070-7.
Ilekis JV, Tsilou E, Fisher S, Abrahams VM, Soares MJ, Cross JC, et al. Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Am J Obstet Gynecol. 2016;215:S1-46. https://doi.org/10.1016/j.ajog.2016.03.001.
Benton SJ, Leavey K, Grynspan D, Cox BJ, Bainbridge SA. The clinical heterogeneity of preeclampsia is related to both placental gene expression and placental histopathology. Am J Obstet Gynecol. 2018;219:604.e1-604.e25. https://doi.org/10.1016/j.ajog.2018.09.036.
Roberts JM, Rich-Edwards JW, McElrath TF, Garmire L, Myatt L. Subtypes of preeclampsia: recognition and determining clinical usefulness. Hypertension. 2021;77:1430–41. https://doi.org/10.1161/HYPERTENSIONAHA.120.14781.
Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019;366. https://doi.org/10.1136/bmj.l2381.
Wójtowicz A, Zembala-Szczerba M, Babczyk D, Kołodziejczyk-Pietruszka M, Lewaczyńska O, Huras H. Early-and late-onset preeclampsia: a comprehensive cohort study of laboratory and clinical findings according to the new ISHHP criteria. Int J Hypertens. 2019. https://doi.org/10.1155/2019/4108271.
Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am J Obstet Gynecol. 2013;209:544.e1-544.e12. https://doi.org/10.1016/j.ajog.2013.08.019.
Guo F, Zhang B, Yang H, Fu Y, Wang Y, Huang J, et al. Systemic transcriptome comparison between early- and late-onset pre-eclampsia shows distinct pathology and novel biomarkers. Cell Prolif. 2021;54. https://doi.org/10.1111/cpr.12968.
Kawasaki K, Kondoh E, Chigusa Y, Kawamura Y, Mogami H, Takeda S, et al. Metabolomic profiles of placenta in preeclampsia: antioxidant effect of magnesium sulfate on trophoblasts in early-onset preeclampsia. Hypertension. 2019;73:671–9. https://doi.org/10.1161/HYPERTENSIONAHA.118.12389.
He J, Yang H, Liu Z, Chen M, Ye Y, Tao Y, et al. Elevated expression of glycolytic genes as a prominent feature of early-onset preeclampsia: insights from integrative transcriptomic analysis. Front Mol Biosci. 2023;10. https://doi.org/10.3389/fmolb.2023.1248771.
Rolfo A, Many A, Racano A, Tal R, Tagliaferro A, Ietta F, et al. Abnormalities in oxygen sensing define early and late onset preeclampsia as distinct pathologies. PLoS ONE. 2010;5. https://doi.org/10.1371/journal.pone.0013288.
Pillay P, Maharaj N, Moodley J, Mackraj I. Placental exosomes and pre-eclampsia: maternal circulating levels in normal pregnancies and early and late onset pre-eclamptic pregnancies. Placenta. 2016;46:18–25. https://doi.org/10.1016/j.placenta.2016.08.078.
Korkes HA, De Oliveira L, Sass N, Salahuddin S, Karumanchi SA, Rajakumar A. Relationship between hypoxia and downstream pathogenic pathways in preeclampsia. Hypertens Pregnancy. 2017;36:145–50. https://doi.org/10.1080/10641955.2016.1259627.
Rajakumar A, Brandon HM, Daftary A, Ness R, Conrad KP. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta. 2004;25:763–9. https://doi.org/10.1016/j.placenta.2004.02.011.
Albogami SM, Al-kuraishy HM, Al-Maiahy TJ, Al-Buhadily AK, Al-Gareeb AI, Alorabi M, et al. Hypoxia-inducible factor 1 and preeclampsia: a new perspective. Curr Hypertens Rep. 2022;24:687–92. https://doi.org/10.1007/s11906-022-01225-1.
Tal R. The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis. Biol Reprod. 2012;87:1–8. https://doi.org/10.1095/biolreprod.112.102723.
Caniggia I, Winter JL. Adriana and Luisa Castellucci Award Lecture 2001: Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal and pre-eclamptic pregnancies - a review. Placenta. 2002;23:S47-57. https://doi.org/10.1053/plac.2002.0815.
Farrell A, Alahari S, Ermini L, Tagliaferro A, Litvack M, Post M, et al. Faulty oxygen sensing disrupts angiomotin function in trophoblast cell migration and predisposes to preeclampsia. JCI Insight. 2019;4. https://doi.org/10.1172/jci.insight.127009.
Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, Zamudio S, et al. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab. 2005;90:4299–308. https://doi.org/10.1210/jc.2005-0078.
Sallais J, Park C, Alahari S, Porter T, Liu R, Kurt M, et al. HIF1 inhibitor acriflavine rescues early-onset preeclampsia phenotype in mice lacking placental prolyl hydroxylase domain protein 2. JCI Insight. 2022;7. https://doi.org/10.1172/jci.
Anton L, Olarerin-George AO, Schwartz N, Srinivas S, Bastek J, Hogenesch JB, et al. MiR-210 inhibits trophoblast invasion and is a serum biomarker for preeclampsia. Am J Pathol. 2013;183:1437–45. https://doi.org/10.1016/j.ajpath.2013.07.021.
Wang H, Zhao Y, Luo R, Bian X, Wang Y, Shao X, et al. A positive feedback self-regulatory loop between miR-210 and HIF-1α mediated by CPEB2 is involved in trophoblast syncytialization: implication of trophoblast malfunction in preeclampsia. Biol Reprod. 2020;102:560–70. https://doi.org/10.1093/biolre/ioz196.
Yuana Y, Böing AN, Grootemaat AE, van der Pol E, Hau CM, Cizmar P, et al. Handling and storage of human body fluids for analysis of extracellular vesicles. J Extracell Vesicles. 2015;4. https://doi.org/10.3402/jev.v4.29260.
Witwer KW, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2. https://doi.org/10.3402/jev.v2i0.20360.
Ramirez MI, Amorim MG, Gadelha C, Milic I, Welsh JA, Freitas VM, et al. Technical challenges of working with extracellular vesicles. Nanoscale. 2018;10:881–906. https://doi.org/10.1039/c7nr08360b.
Palviainen M, Saraswat M, Varga Z, Kitka D, Neuvonen M, Puhka M, et al. Extracellular vesicles from human plasma and serum are carriers of extravesicular cargo—implications for biomarker discovery. PLoS ONE. 2020;15:1–19. https://doi.org/10.1371/journal.pone.0236439.
Royo F, Théry C, Falcón-Pérez JM, Nieuwland R, Witwer KW. Methods for separation and characterization of extracellular vesicles: results of a worldwide survey performed by the ISEV Rigor and Standardization Subcommittee. Cells. 2020;9. https://doi.org/10.3390/cells9091955.
Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7. https://doi.org/10.1080/20013078.2018.1535750
Salomon C, Torres MJ, Kobayashi M, Scholz-Romero K, Sobrevia L, Dobierzewska A, et al. A gestational profile of placental exosomes in maternal plasma and their effects on endothelial cell migration. PLoS ONE. 2014;9. https://doi.org/10.1371/journal.pone.0098667.
Palma C, McIntyre HD, Salomon C. Extracellular vesicles—new players in cell-to-cell communication in gestational diabetes mellitus. Biomedicines. 2022;10. https://doi.org/10.3390/biomedicines10020462.
Rani S, Lai A, Nair S, Sharma S, Handberg A, Carrion F, et al. Extracellular vesicles as mediators of cell-cell communication in ovarian cancer and beyond – a lipids focus. Cytokine Growth Factor Rev. 2023. https://doi.org/10.1016/j.cytogfr.2023.06.004.
Mathivanan S, Fonseka P, Nedeva C, Atukorala I, editors. New frontiers: extracellular vesicles. Subcellular Biochemistry (SCBI, volume 97). Springer; 2021.
Zierden HC, Marx-Rattner R, Rock KD, Montgomery KR, Anastasiadis P, Folts L, et al. Extracellular vesicles are dynamic regulators of maternal glucose homeostasis during pregnancy. Sci Rep. 2023;13. https://doi.org/10.1038/s41598-023-31425-x.
Guay C, Regazzi R. Exosomes as new players in metabolic organ cross-talk. Diabetes Obes Metab. 2017;19:137–46. https://doi.org/10.1111/dom.13027.
Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9. https://doi.org/10.1038/ncb1596.
Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21:9–17. https://doi.org/10.1038/s41556-018-0250-9.
Adam S, Elfeky O, Kinhal V, Dutta S, Lai A, Jayabalan N, et al. Review: fetal-maternal communication via extracellular vesicles – implications for complications of pregnancies. Placenta. 2017;54:83–8. https://doi.org/10.1016/j.placenta.2016.12.001.
Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman LJ, et al. Reassessment of exosome composition. Cell. 2019;177:428-445.e18. https://doi.org/10.1016/j.cell.2019.02.029.
Gilani SI, Weissgerber TL, Garovic VD, Jayachandran M. Preeclampsia and extracellular vesicles. Curr Hypertens Rep. 2016;18. https://doi.org/10.1007/s11906-016-0678-x.
Nakahara A, Nair S, Ormazabal V, Elfeky O, Garvey CE, Longo S, et al. Circulating placental extracellular vesicles and their potential roles during pregnancy. Ochsner J. 2020;20:439–45. https://doi.org/10.31486/toj.20.0049.
Sarker S, Scholz-Romero K, Perez A, Illanes SE, Mitchell MD, Rice GE, et al. Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. J Transl Med. 2014;12. https://doi.org/10.1186/1479-5876-12-204.
Pillay P, Moodley K, Moodley J, Mackraj I. Placenta-derived exosomes: potential biomarkers of preeclampsia. Int J Nanomed. 2017;12:8009–23. https://doi.org/10.2147/IJN.S142732.
Ormazabal V, Nair S, Carrión F, Mcintyre HD, Salomon C. The link between gestational diabetes and cardiovascular diseases: potential role of extracellular vesicles. Cardiovasc Diabetol. 2022;21. https://doi.org/10.1186/s12933-022-01597-3.
Schuster J, Cheng SB, Padbury J, Sharma S. Placental extracellular vesicles and pre-eclampsia. Am J Reprod Immunol. 2021;85. https://doi.org/10.1111/aji.13297.
Ghafourian M, Mahdavi R, Akbari Jonoush Z, Sadeghi M, Ghadiri N, Farzaneh M, et al. The implications of exosomes in pregnancy: emerging as new diagnostic markers and therapeutics targets. Cell Commun Signal. 2022;20. https://doi.org/10.1186/s12964-022-00853-z.
Sadovsky Y, Ouyang Y, Powell JS, Li H, Mouillet JF, Morelli AE, et al. Placental small extracellular vesicles: Current questions and investigative opportunities. Placenta. 2020;102:34–8. https://doi.org/10.1016/j.placenta.2020.03.002.
Lawson C, Vicencio JM, Yellon DM, Davidson SM. Microvesicles and exosomes: new players in metabolic and cardiovascular disease. J Endocrinol. 2016;228:R57-71. https://doi.org/10.1530/JOE-15-0201.
Wu JY, Li YJ, Hu XB, Huang S, Xiang DX. Preservation of small extracellular vesicles for functional analysis and therapeutic applications: a comparative evaluation of storage conditions. Drug Deliv. 2021;28:162–70. https://doi.org/10.1080/10717544.2020.1869866.
Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148–69. https://doi.org/10.1016/j.preghy.2021.09.008.
Comfort N, Cai K, Bloomquist TR, Strait MD, Ferrante AW, Baccarelli AA. Nanoparticle tracking analysis for the quantification and size determination of extracellular vesicles. J Vis Exp. 2021;(169). https://doi.org/10.3791/62447.
Roberts JM, Escudero C. The placenta in preeclampsia Pregnancy Hypertens. 2012;2:72–83. https://doi.org/10.1016/j.preghy.2012.01.001.
Iriyama T, Wang W, Parchim NF, Song A, Blackwell SC, Sibai BM, et al. Hypoxia-independent upregulation of placental hypoxia inducible factor-1α gene expression contributes to the pathogenesis of preeclampsia. Hypertension. 2015;65:1307–15. https://doi.org/10.1161/HYPERTENSIONAHA.115.05314.
Sriyanti R, Mose JC, Masrul M, Suharti N. The difference in maternal serum hypoxia-inducible factors-1α levels between early onset and late-onset preeclampsia. Maced J Med Sci. 2019;7:2133–7. https://doi.org/10.3889/oamjms.2019.601.
Zhao L, Ma R, Zhang L, Yuan X, Wu J, He L, et al. Inhibition of HIF-1a-mediated TLR4 activation decreases apoptosis and promotes angiogenesis of placental microvascular endothelial cells during severe pre-eclampsia pathogenesis. Placenta. 2019;83:8–16. https://doi.org/10.1016/j.placenta.2019.06.375.
Anton L, De Vine A, Polyak E, Olarerin-George A, Brown AG, Falk MJ, et al. HIF-1α stabilization increases miR-210 eliciting first trimester extravillous trophoblast mitochondrial dysfunction. Front Physiol. 2019;10:1–12. https://doi.org/10.3389/fphys.2019.00699.
Jaszczuk I, Koczkodaj D, Kondracka A, Kwaśniewska A, Winkler I, Filip A. The role of miRNA-210 in pre-eclampsia development. Ann Med. 2022;54:1350–6. https://doi.org/10.1080/07853890.2022.2071459.
Guan Y, Song X, Sun W, Wang Y, Liu B. Effect of hypoxia-induced MicroRNA-210 expression on cardiovascular disease and the underlying mechanism. Oxid Med Cell Longev. 2019;2019. https://doi.org/10.1155/2019/4727283.
Zhang Y, Fei M, Xue G, Zhou Q, Jia Y, Li L, et al. Elevated levels of hypoxia-inducible microRNA-210 in pre-eclampsia: new insights into molecular mechanisms for the disease. J Cell Mol Med. 2012;16:249–59. https://doi.org/10.1111/j.1582-4934.2011.01291.x.
Gan L, Liu Z, Wei M, Chen Y, Yang X, Chen L, et al. MiR-210 and miR-155 as potential diagnostic markers for pre-eclampsia pregnancies. Medicine. 2017;96. https://doi.org/10.1097/MD.0000000000007515.
Biró O, Alasztics B, Molvarec A, Joó J, Nagy B, Rigó J. Various levels of circulating exosomal total-miRNA and miR-210 hypoxamiR in different forms of pregnancy hypertension. Pregnancy Hypertens. 2017;10:207–12. https://doi.org/10.1016/j.preghy.2017.09.002.
Colleoni F, Padmanabhan N, Yung H, Watson ED, Cetin I, Tissot van Patot MC, et al. Suppression of mitochondrial electron transport chain function in the hypoxic human placenta: a role for miRNA-210 and protein synthesis inhibition. PLoS ONE. 2013;8. https://doi.org/10.1371/journal.pone.0055194.
Luo R, Wang Y, Xu P, Cao G, Zhao Y, Shao X, et al. Hypoxia-inducible miR-210 contributes to preeclampsia via targeting thrombospondin type I domain containing 7A. Sci Rep. 2016;6. https://doi.org/10.1038/srep19588.
Luo R, Shao X, Xu P, Lui Y, Wang Y, Zhao Y, et al. MicroRNA-210 contributes to preeclampsia by downregulating potassium channel modulatory factor 1. Hypertension. 2014;64:839–45.
Muralimanoharan S, Maloyan A, Mele J, Guo C, Myatt LG, Myatt L. MIR-210 modulates mitochondrial respiration in placenta with preeclampsia. Placenta. 2012;33:816–23. https://doi.org/10.1016/j.placenta.2012.07.002.
Lee DC, Romero R, Kim JS, Tarca AL, Montenegro D, Pineles BL, et al. MiR-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm preeclampsia and small-for-gestational-age pregnancies. Am J Pathol. 2011;179:590–602. https://doi.org/10.1016/j.ajpath.2011.04.035.
Salomon C, Yee S, Scholz-Romero K, Kobayashi M, Vaswani K, Kvaskoff D, et al. Extravillous trophoblast cells-derived exosomes promote vascular smooth muscle cell migration. Front Pharmacol. 2014;5. https://doi.org/10.3389/fphar.2014.00175.
Jayabalan N, Nair S, Nuzhat Z, Rice GE, Zuñiga FA, Sobrevia L, et al. Cross talk between adipose tissue and placenta in obese and gestational diabetes mellitus pregnancies via exosomes. Front Endocrinol (Lausanne). 2017;8. https://doi.org/10.3389/fendo.2017.00239.
James-Allan LB, Rosario FJ, Madi L, Barner K, Nair S, Lai A, et al. A novel technique using chronic infusion of small extracellular vesicles from gestational diabetes mellitus causes glucose intolerance in pregnant mice. Clin Sci. 2022;136:1535–49. https://doi.org/10.1042/CS20220484.
Truong G, Guanzon D, Kinhal V, Elfeky O, Lai A, Longo S, et al. Oxygen tension regulates the miRNA profile and bioactivity of exosomes released from extravillous trophoblast cells-liquid biopsies for monitoring complications of pregnancy. PLoS ONE. 2017;12. https://doi.org/10.1371/journal.pone.0174514.
Mitchell MD, Peiris HN, Kobayashi M, Koh YQ, Duncombe G, Illanes SE, et al. Placental exosomes in normal and complicated pregnancy. Am J Obstet Gynecol. 2015;213:S173–81. https://doi.org/10.1016/j.ajog.2015.07.001.
Tannetta D, Masliukaite I, Vatish M, Redman C, Sargent I. Update of syncytiotrophoblast derived extracellular vesicles in normal pregnancy and preeclampsia. J Reprod Immunol. 2017;119:98–106. https://doi.org/10.1016/j.jri.2016.08.008.
Mincheva-Nilsson L, Baranov V. The role of placental exosomes in reproduction. Am J Reprod Immunol. 2010;63:520–33. https://doi.org/10.1111/j.1600-0897.2010.00822.x.
Smith TI, Russell AE. Extracellular vesicles in reproduction and pregnancy. Extracell Vesicles Circ Nucl Acids. 2022;3:292–317. https://doi.org/10.20517/evcna.2022.27.
Salomon C, Yee SW, Mitchell MD, Rice GE. The possible role of extravillous trophoblast-derived exosomes on the uterine spiral arterial remodeling under both normal and pathological conditions. Biomed Res Int. 2014;2014. https://doi.org/10.1155/2014/693157.
Escudero CA, Herlitz K, Troncoso F, Acurio J, Aguayo C, Roberts JM, et al. Role of extracellular vesicles and microRNAs on dysfunctional angiogenesis during preeclamptic pregnancies. Front Physiol. 2016;7. https://doi.org/10.3389/fphys.2016.00098.
Aharon A, Rebibo-Sabbah A, Ahmad RS, Dangot A, Bar-Lev TH, Brenner B, et al. Associations of maternal and placental extracellular vesicle miRNA with preeclampsia. Front Cell Dev Biol. 2023;11. https://doi.org/10.3389/fcell.2023.1080419.
Miranda J, Paules C, Nair S, Lai A, Palma C, Scholz-Romero K, et al. Placental exosomes profile in maternal and fetal circulation in intrauterine growth restriction - liquid biopsies to monitoring fetal growth. Placenta. 2018;64:34–43. https://doi.org/10.1016/j.placenta.2018.02.006.
Menon R, Debnath C, Lai A, Guanzon D, Bhatnagar S, Kshetrapal PK, et al. Circulating exosomal miRNA profile during term and preterm birth pregnancies: a longitudinal study. Endocrinology. 2019;160:249–75. https://doi.org/10.1210/en.2018-00836.
Chen HY, Wang XY, Lu KM, Yu CH, Su MT, Kang L, et al. Maternal Th17/Treg cytokines and small extracellular vesicles in plasma as potential biomarkers for preeclampsia. Int J Med Sci. 2022;19:1672–9. https://doi.org/10.7150/ijms.71047.
Chaemsaithong P, Luewan S, Taweevisit M, Chiangjong W, Pongchaikul P, Thorner PS, et al. Placenta-derived extracellular vesicles in pregnancy complications and prospects on a liquid biopsy for hemoglobin Bart’s disease. Int J Mol Sci. 2023;24. https://doi.org/10.3390/ijms24065658.
Dixon CL, Sheller-Miller S, Saade GR, Fortunato SJ, Lai A, Palma C, et al. Amniotic fluid exosome proteomic profile exhibits unique pathways of term and preterm labor. Endocrinology. 2018;159:2229–40. https://doi.org/10.1210/en.2018-00073.
Staff AC. The two-stage placental model of preeclampsia: an update. J Reprod Immunol. 2019;134–135:1–10. https://doi.org/10.1016/j.jri.2019.07.004.
Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. 2008;51:970–5. https://doi.org/10.1161/HYPERTENSIONAHA.107.107607.
Awoyemi T, Cerdeira AS, Zhang W, Jiang S, Rahbar M, Logenthiran P, et al. Preeclampsia and syncytiotrophoblast membrane extracellular vesicles (STB-EVs). Clin Sci. 2022;136:1793–807. https://doi.org/10.1042/CS20220149.
Goswamia D, Tannetta DS, Magee LA, Fuchisawa A, Redman CWG, Sargent IL, et al. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta. 2006;27:56–61. https://doi.org/10.1016/j.placenta.2004.11.007.
Dragovic RA, Southcombe JH, Tannetta DS, Redman CWG, Sargent IL. Multicolor flow cytometry and nanoparticle tracking analysis of extracellular vesicles in the plasma of normal pregnant and pre-eclamptic women. Biol Reprod. 2013;89. https://doi.org/10.1095/biolreprod.113.113266.
Villalobos-Labra R, Liu R, Spaans F, Sáez T, Quon A, Wong M, et al. Placenta-derived extracellular vesicles from preeclamptic and healthy pregnancies impair ex vivo vascular endothelial function. Biosci Rep. 2022;42. https://doi.org/10.1042/BSR20222185.
Redman CWG, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol. 2015;213:S9.e1-S9.e4. https://doi.org/10.1016/j.ajog.2015.08.003.
Redman CWG, Tannetta DS, Dragovic RA, Gardiner C, Southcombe JH, Collett GP, et al. Review: does size matter? placental debris and the pathophysiology of pre-eclampsia. Placenta. 2012;33. https://doi.org/10.1016/j.placenta.2011.12.006.
Sheikh AM, Small HY, Currie G, Delles C. Systematic review of micro-RNA expression in pre-eclampsia identifies a number of common pathways associated with the disease. PLoS ONE. 2016;11. https://doi.org/10.1371/journal.pone.0160808.
Kolkova Z, Holubekova V, Grendar M, Nachajova M, Zubor P, Pribulova T, et al. Association of circulating miRNA expression with preeclampsia, its onset, and severity. Diagnostics. 2021;11. https://doi.org/10.3390/diagnostics11030476.
Aga M, Bentz GL, Raffa S, Torrisi MR, Kondo S, Wakisaka N, et al. Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene. 2014;33:4613–22. https://doi.org/10.1038/onc.2014.66.
Vasco Ferreira J, da Rosa SA, Ramalho J, Máximo Carvalho C, Helena Cardoso M, Pintado P, et al. LAMP2A regulates the loading of proteins into exosomes. Sci Adv. 2022;8:1–19. https://doi.org/10.1126/sciadv.abm1140.
Funding
This work was supported in part by AMAG Pharmaceuticals research grant #GN671265, the Nicholas J Thompson Distinguished Professor Research Grant, Wright State University and Premier Health Neuroscience Institute and Wright State University Endowment for Research on Pregnancy Associated Disorders. We would like to thank the Travers lab at Wright State University for use of the Nanosight instrumentation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Declarations
The authors have no competing interests to declare that are relevant to the content of this article. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.
Conflicts of Interest\Competing Interest
Not applicable.
Ethics Approval
Ethics approval by committee for research involving humans.
Consent to Participate
All subjects were informed and gave written consent prior to their participation in this study.
Consent for Publication
All authors have reviewed and agreed to publication.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Bowman-Gibson, S., Chandiramani, C., Stone, M.L. et al. Streamlined Analysis of Maternal Plasma Indicates Small Extracellular Vesicles are Significantly Elevated in Early-Onset Preeclampsia. Reprod. Sci. 31, 2771–2782 (2024). https://doi.org/10.1007/s43032-024-01591-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43032-024-01591-y